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Abstract
Background: Frail older adults living in residential aged care facilities (RACFs) usually experience comorbidities and
are frequently prescribed multiple medications. This increases the potential risk of inappropriate prescribing and its
negative consequences. Thus, optimising prescribed medications in RACFs is a challenge for healthcare providers.
Objective: Our aim was to systematically review interventions that increase the appropriateness of medications
used in RACFs and the outcomes of these interventions.
Methods: Systematic review and meta-analysis of randomised control trials (RCTs) and cluster randomised control
trials (cRCTs) were performed by searching specified databases (MEDLINE, PubMed, Google scholar, PsycINFO) for
publications from inception to May 2019 based on defined inclusion criteria. Data were extracted, study quality was
assessed and statistically analysed using RevMan v5.3. Medication appropriateness, hospital admissions, mortality,
falls, quality of life (QoL), Behavioural and Psychological Symptoms of Dementia (BPSD), adverse drug events (ADEs)
and cognitive function could be meta-analysed.
Results: A total of 25 RCTs and cRCTs comprising 19,576 participants met the inclusion criteria. The studies tested
various interventions including medication review (n = 13), staff education (n = 9), multi-disciplinary case
conferencing (n = 4) and computerised clinical decision support systems (n = 2). There was an effect of interventions
on medication appropriateness (RR 0.71; 95% confidence interval (CI): 0.60,0.84) (10 studies), and on medication
appropriateness scales (standardised mean difference = − 0.67; 95% CI: − 0.97, − 0.36) (2 studies). There were no
apparent effects on hospital admission (RR 1.00; 95% CI: 0.93, 1.06), mortality (RR 0.98; 95% CI: 0.86, 1.11), falls (RR
1.06; 95% CI: 0.89,1.26), ADEs (RR 1.04; 95% CI: 0.96,1.13), QoL (standardised mean difference = 0.16; 95% CI:-0.13,
0.45), cognitive function (weighted mean difference = 0.69; 95% CI: − 1.25, 2.64) and BPSD (RR 0.68; 95% CI: 0.44,
1.06) (2 studies).
Conclusion: Modest improvements in medication appropriateness were observed in the studies included in this
systematic review. However, the effect on clinical measures was limited to drive strong conclusions.
Keywords: Medication optimisation, Intervention, Elderly, Systematic review, Aged care facility, Clinical outcomes,
Meta-analysis
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: phhend@hotmail.com
1Medical school, University of Western Australia, Perth, Australia
Full list of author information is available at the end of the article
Almutairi et al. BMC Geriatrics          (2020) 20:236 
https://doi.org/10.1186/s12877-020-01634-4
Ta
b
le
1
St
ud
y
ch
ar
ac
te
ris
tic
s
of
th
e
in
cl
ud
ed
st
ud
ie
s
St
ud
y
ID
A
ut
ho
r
Ye
ar
C
ou
nt
ry
D
es
ig
n
Se
tt
in
g
Sa
m
pl
e
si
ze
A
ge
In
te
rv
en
tio
n
Fo
llo
w
-
up
O
ut
co
m
es
Su
m
m
ar
y
of
re
su
lts
1
A
vo
rn
et
al
.
[1
4]
19
92
U
SA
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
s=
12
N
H
R
=
82
3
65 an
d
ol
de
r
-
ph
ys
ic
ia
ns
w
ho
is
th
er
e
pr
es
cr
ib
in
g
of
ps
yc
ho
ac
tiv
e
dr
ug
s
w
as
ab
ov
e
th
re
sh
ol
d
at
th
e
ba
se
lin
e
ev
al
ua
tio
n
w
er
e
in
vi
te
d
by
ph
ar
m
ac
is
ts
fo
r
se
pa
ra
te
se
ss
io
ns
(3
in
te
ra
ct
iv
e
vi
si
ts
).
-
A
ll
ph
ys
ic
ia
ns
of
N
H
R
re
ce
iv
ed
6
lit
er
at
ur
e
su
m
m
ar
ie
s
(in
so
m
ni
a,
be
ha
vi
ou
ra
lp
ro
bl
em
s)
in
3
m
ai
lin
gs
.
-
4
tr
ai
ni
ng
se
ss
io
ns
w
er
e
de
liv
er
ed
to
nu
rs
es
/
nu
rs
in
g
as
si
st
an
ts
on
ge
ria
tr
ic
ph
ar
m
a
ps
yc
ho
lo
gy
,a
lte
rn
at
iv
es
to
ps
yc
ho
ac
tiv
e
dr
ug
s
5 m
on
th
s
-p
sy
ch
oa
ct
iv
e
dr
ug
us
e
sc
or
es
-p
ro
po
rt
io
n
of
re
si
de
nt
s
us
in
g
an
tip
sy
ch
ot
ic
s.
-p
sy
ch
oa
ct
iv
e
dr
ug
us
e
m
ea
n
in
in
te
rv
en
tio
n
27
%
co
m
pa
re
d
to
80
%
in
co
nt
ro
lg
ro
up
(P
=
0.
02
).
-a
nt
ip
sy
ch
ot
ic
s
ce
as
ed
in
in
te
rv
en
tio
n
32
%
ve
rs
us
14
%
in
co
nt
ro
l.
-
no
of
da
ys
/p
at
ie
nt
/
m
on
th
gr
ea
tly
re
du
ce
d
in
in
te
rv
en
tio
n
th
an
co
nt
ro
l.
-n
o
of
no
n-
re
co
m
m
en
de
d
hy
pn
ot
ic
s
ce
as
ed
an
d
su
bs
tit
ut
ed
w
ith
al
te
rn
at
iv
e
dr
ug
s/
di
sc
on
tin
ue
d
co
m
pl
et
el
y
w
er
e
45
%
in
in
te
rv
en
tio
n
ve
rs
us
21
%
co
nt
ro
l.
2
Ro
vn
er
et
al
.[
15
]
19
96
U
SA
RC
T
N
ur
si
ng
ho
m
es
1
N
H
(2
50
be
d
co
m
m
un
ity
N
H
)
N
H
R
=
89
65 an
d
ol
de
r
-A
s
ap
ar
t
of
a
de
m
en
tia
ca
re
pr
og
ra
m
:
im
pl
em
en
ta
tio
n
of
ne
w
pr
es
cr
ib
in
g
gu
id
el
in
es
ba
se
d
on
pr
ot
oc
ol
fo
r
ps
yc
ho
tr
op
ic
dr
ug
m
an
ag
em
en
t
-E
du
ca
tio
na
lr
ou
nd
s
w
ee
kl
y
fo
r
1
h
to
di
sc
us
s
pa
tie
nt
’s
be
ha
vi
ou
ra
ld
is
or
de
rs
,
an
d
m
ed
ic
al
st
at
us
6 m
on
th
s
-
an
tip
sy
ch
ot
ic
dr
ug
-
be
ha
vi
ou
r
di
so
rd
er
s
-r
es
tr
ai
nt
us
e,
-
an
d
co
gn
iti
ve
/
fu
nc
tio
na
l
st
at
us
.
-S
ta
tis
tic
al
ly
si
gn
ifi
ca
nt
71
%
re
du
ct
io
n
in
ag
ita
tio
n
w
ith
in
te
rv
en
tio
n
ve
rs
us
49
%
w
ith
co
nt
ro
l
3
M
ea
do
r
et
al
.[
16
]
19
97
U
SA
RC
T
N
ur
si
ng
ho
m
es
N
H
s=
12
N
H
R
=
13
11
65 an
d
ol
de
r
-g
er
op
sy
ch
ia
tr
is
t
de
liv
er
ed
ed
uc
at
io
na
l
vi
si
t
to
ph
ys
ic
ia
ns
(4
5-
60
m
in
)
-N
H
st
af
f
re
ce
iv
ed
5–
6
1-
h
pr
og
ra
m
m
es
ov
er
1
w
ee
k
de
liv
er
ed
by
nu
rs
e
ed
uc
at
or
.
-a
ft
er
1
m
on
th
,f
ol
lo
w
up
se
ss
io
ns
-
w
he
n
re
qu
es
te
d,
ev
en
in
g
m
ee
tin
gs
fo
r
fa
m
ili
es
.
6 m
on
th
s
-P
ro
po
rt
io
n
of
A
Ps
dr
ug
us
e
in
da
ys
/
10
0
/d
ay
s
of
st
ay
.
-s
ev
er
ity
an
d
pr
es
en
ce
of
be
ha
vi
ou
ra
l
sy
m
pt
om
s.
-A
Ps
us
e
pe
r
10
0
da
ys
at
ba
se
lin
e
in
in
te
rv
en
tio
n
gp
de
cr
ea
se
d
fro
m
25
.3
da
ys
to
19
.7
pe
r
10
0.
-A
ps
re
du
ct
io
n
is
23
%
in
in
te
rv
en
tio
n
gp
to
co
nt
ro
lg
p.
−
33
%
N
H
R
in
in
te
rv
en
tio
n
gp
ha
d
th
ei
r
an
tip
sy
ch
ot
ic
s
ce
as
ed
.
4
Sc
hm
id
t
et
al
.1
&2
[1
7,
18
]
19
98
Sw
ed
en
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
33
N
H
R
=
18
54
65 an
d
ol
de
r
-M
on
th
ly
m
ul
tid
is
ci
pl
in
ar
y
m
ee
tin
gs
le
d
by
ph
ar
m
ac
is
t
fo
r
12
m
on
th
s
12 m
on
th
s
-P
ro
po
rt
io
n
of
re
si
de
nt
s
w
ith
ps
yc
ho
tr
op
ic
s
-n
on
re
co
m
m
en
de
d
hy
pn
ot
ic
s,
an
tid
ep
re
ss
an
ts
.
−
19
%
of
re
si
de
nt
s
in
th
e
in
te
rv
en
tio
n
gp
ce
as
ed
A
Ps
(p
=
0.
00
7)
.
−
37
%
of
re
si
de
nt
s
ce
as
ed
no
n-
re
co
m
m
en
de
d
hy
pn
ot
ic
s
in
in
te
rv
en
tio
n
gp
(p
<
0.
00
1)
.
Sc
hm
id
t
et
al
.[
19
]
20
00
Sw
ed
en
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
36
N
H
R
=
15
49
65 an
d
ol
de
r
N
ur
si
ng
ho
m
es
pa
rt
ic
ip
at
ed
in
19
95
w
er
e
fo
llo
w
ed
up
.
th
re
e-
ye
ar
fo
llo
w
-
up
M
ed
ic
at
io
n
ap
pr
op
ria
te
ne
ss
-p
ro
po
rt
io
n
of
re
si
de
nt
s
pr
es
cr
ib
ed
no
n-
re
co
m
m
en
de
d
hy
pn
ot
ic
s
w
er
e
lo
w
er
(1
4.
0%
)c
om
pa
re
d
to
pr
ev
io
us
st
ud
y
19
95
(1
9.
0%
).
-
in
19
98
5%
of
re
si
de
nt
s
w
er
e
pr
es
cr
ib
ed
no
n
re
co
m
m
en
de
d
hy
pn
ot
ic
s
co
m
pa
re
d
to
co
nt
ro
lg
p
(1
0.
1%
).
C
la
es
so
n
et
al
.[
20
]
19
98
Sw
ed
en
C
lu
st
er
-
RC
T
N
ur
si
ng
ho
m
es
N
H
=
33
N
H
R
=
18
54
65 an
d
ol
de
r
-
re
gu
la
r
m
ul
tid
is
ci
pl
in
ar
y
m
ee
tin
gs
(p
hy
si
ci
an
,p
ha
rm
ac
is
t,
N
H
nu
rs
es
/
as
si
st
an
t)
re
vi
ew
ed
re
si
de
nt
’s
dr
ug
us
e
on
a
m
on
th
ly
ba
si
s
ov
er
12
m
on
th
s.
14 m
on
th
s
M
ed
ic
at
io
n-
re
la
te
d
pr
ob
le
m
s
-N
H
re
si
de
nt
s
w
er
e
pr
es
cr
ib
ed
on
av
er
ag
e
7.
7o
(ra
ng
e:
6–
11
)
m
ed
ic
at
io
ns
.
-
la
xa
tiv
es
(7
0%
)
Almutairi et al. BMC Geriatrics          (2020) 20:236 Page 2 of 19
Ta
b
le
1
St
ud
y
ch
ar
ac
te
ris
tic
s
of
th
e
in
cl
ud
ed
st
ud
ie
s
(C
on
tin
ue
d)
St
ud
y
ID
A
ut
ho
r
Ye
ar
C
ou
nt
ry
D
es
ig
n
Se
tt
in
g
Sa
m
pl
e
si
ze
A
ge
In
te
rv
en
tio
n
Fo
llo
w
-
up
O
ut
co
m
es
Su
m
m
ar
y
of
re
su
lts
-e
du
ca
tio
n
fo
r
se
le
ct
ed
ph
ar
m
ac
is
ts
(5
oc
ca
si
on
s
=
65
.5
h)
,t
op
ic
s
w
er
e
dr
ug
us
e
in
el
de
rly
,g
er
ia
tr
ic
s.
-p
sy
ch
ot
ro
pi
c
dr
ug
s
(7
7%
,r
an
ge
:5
0–
95
%
).
5
Fu
rn
is
s
et
al
.
[2
1]
20
00
En
gl
an
d.
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
14
N
H
R
=
33
0
re
si
de
nt
s:
(1
72
ct
rl,
15
8
In
t)
65 an
d
ol
de
r
-M
ed
ic
at
io
n
re
vi
ew
le
d
by
ph
ar
m
ac
is
t.
-
ph
ar
m
ac
is
t
re
vi
ew
th
e
m
ed
ic
at
io
ns
at
N
H
,G
Ps
su
rg
er
y,
or
ov
er
ph
on
e.
-P
ha
rm
ac
is
t
co
lle
ct
ed
de
ta
ils
of
cu
rr
en
t
m
ed
ic
at
io
n,
m
ed
ic
al
hi
st
or
y
an
d
cu
rr
en
t
pr
ob
le
m
id
en
tif
ie
d
by
nu
rs
in
g
ho
m
e
st
af
f.
-
3
w
ee
ks
po
st
-m
ed
ic
in
e
re
vi
ew
,N
H
w
er
e
re
vi
si
te
d
to
id
en
tif
y
an
y
pr
ob
-
le
m
s
an
d
to
as
ce
rt
ai
n
on
w
he
th
er
ch
an
ge
s
ha
d
be
en
im
pl
em
en
te
d.
8 m
on
th
s
-n
o
of
pr
es
cr
ib
ed
m
ed
ic
at
io
ns
-T
yp
es
of
m
ed
ic
at
io
ns
,
re
as
on
fo
r
us
in
g
ne
ur
ol
ep
tic
m
ed
ic
at
io
ns
.
-h
os
pi
ta
l
ad
m
is
si
on
(in
-
pa
tie
nt
da
ys
)
-M
M
SE
-G
D
S
-B
A
SD
EC
-C
RB
RS
-F
al
ls
an
d
de
at
h
-
23
9
of
re
co
m
m
en
da
tio
ns
ac
ce
pt
ed
by
G
P
(9
1.
6%
).
-c
ha
ng
e
of
m
ed
ic
at
io
ns
=
14
4
-In
to
ta
lM
M
SE
w
er
e
de
cl
in
ed
.
-
M
ea
n
C
RB
RS
sc
or
es
in
cr
ea
se
d
in
In
t
co
m
pa
re
d
to
ct
rl
-
de
at
hs
in
ct
rl
w
er
e
hi
gh
er
th
an
In
t
N
H
s.
6
St
ei
n
et
al
.
[2
2]
20
01
U
SA
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
20
N
H
R
=
14
7
65 an
d
ol
de
r
-S
ta
ff
tr
ai
ni
ng
se
ss
io
ns
(3
0
m
in
)
-S
tu
dy
ph
ys
ic
ia
n
vi
si
te
d/
te
le
ph
on
e
to
al
l
pr
im
ar
y
ca
re
ph
ys
ic
ia
ns
-p
hy
si
ci
an
s
re
ce
iv
ed
m
es
sa
ge
s
ab
ou
t
N
SA
ID
s
ris
ks
an
d
be
ne
fit
s
,a
lg
or
ith
m
fo
r
st
op
pi
ng
N
SA
ID
s,
or
at
er
na
tiv
es
su
ch
as
pa
ra
ce
ta
m
ol
or
to
pi
ca
la
ge
nt
s
an
d
no
n-
ph
ar
m
ac
ol
og
ic
al
m
an
ag
em
en
t
fo
r
pa
in
.
3 m
on
th
s
N
SA
ID
s
an
d
pa
ra
ce
ta
m
ol
U
se
in
th
e
pa
st
w
ee
k
-M
ea
n
nu
m
be
r
of
da
ys
of
N
SA
ID
s
us
e
de
ce
as
ed
in
In
t
gp
fro
m
7.
0–
1.
9
da
ys
co
m
pa
re
d
to
ct
rl
gp
(7
.0
–6
.2
da
ys
),
P
=
0.
00
01
-
pa
ra
ce
ta
m
ol
us
e
in
In
t
gp
in
cr
ea
se
d
(3
.1
da
ys
)c
om
pa
re
d
to
ct
rl
(0
.3
1
da
ys
),
P
=
0.
00
01
.
7
Ro
be
rt
s
et
al
.[
23
]
20
01
A
us
tr
al
ia
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
52
N
H
R
=
32
30
65 an
d
ol
de
r
-n
ur
se
ed
uc
at
io
n
(6
–9
pr
ob
le
m
-b
as
ed
ed
uc
at
io
n
se
ss
io
ns
)
in
cl
ud
in
g
ge
ria
tr
ic
m
ed
ic
at
io
ns
an
d
co
m
m
on
pr
ob
le
m
s
in
lo
ng
ca
re
su
ch
as
de
pr
es
si
on
&
pa
in
.
-s
up
po
rt
ed
by
bu
lle
tin
s,
w
al
lc
ha
rt
s
an
d
cl
in
ic
al
ph
ar
m
ac
is
t
vi
si
ts
.
-
cl
in
ic
al
ph
ar
m
ac
is
t
av
er
ag
e
co
nt
ac
t
26
h/
N
H
-c
lin
ic
al
ph
ar
m
ac
is
t
re
vi
ew
ed
dr
ug
re
gi
m
en
fo
r
50
0
re
si
de
nt
s
se
le
ct
ed
by
ho
m
e
st
af
f.
12 m
on
th
s
-M
or
ta
lit
y
ra
te
-h
os
pi
ta
l
ad
m
is
si
on
-D
ru
g
us
e
-A
D
Es
-M
ed
ic
at
io
n-
re
la
te
d
pr
ob
le
m
s
-m
ea
n
no
of
ps
yc
ho
le
pt
ic
s
ad
m
in
is
te
re
d
/r
es
id
en
t
in
In
t
gp
de
cr
ea
se
d
(−
0.
14
,
95
%
C
I−
0.
28
-0
.0
,p
=
0.
04
4)
-
in
th
e
in
te
rv
en
tio
n
gr
ou
p
m
ea
n
nu
m
be
r
of
be
nz
od
ia
ze
pi
ne
s
A
dm
in
is
te
re
d/
re
si
de
nt
re
du
ce
d
(−
0.
06
,9
5%
C
I−
0.
06
to
0.
04
,p
=
0.
29
).
8
C
ro
tt
y
et
al
.
(a
)
[2
4]
20
04
A
us
tr
al
ia
C
lu
st
er
RC
T
A
ge
d
ca
re
fa
ci
lit
y
N
H
=
10
N
H
R
=
15
4
65 an
d
ol
de
r
−
2
m
ul
tid
is
ci
pl
in
ar
y
ca
se
co
nf
er
en
ce
s
w
er
e
co
nd
uc
te
d
6–
12
w
ee
ks
.
-p
ha
rm
ac
is
ts
,g
er
ia
tr
ic
ia
n,
re
si
de
nt
ia
l
ca
re
st
af
f,
G
P,
an
d
a
re
pr
es
en
ta
tiv
e
of
th
e
A
lz
he
im
er
’s
A
ss
oc
ia
tio
n
of
So
ut
h
A
us
tr
al
ia
.
-m
ed
ic
at
io
n
re
vi
ew
pr
ep
ar
ed
by
th
e
7 m
on
th
s
-M
A
Is
co
re
-M
ea
n
M
A
Is
co
re
in
In
t
gp
4.
1
(2
.1
–6
.1
)
ve
rs
us
0.
4
(0
.4
–1
.2
)i
n
ct
rl
gp
.
-
be
nz
od
ia
ze
pi
ne
s:
m
ea
n
M
A
Is
co
re
in
in
t.g
p
0.
73
(0
.1
6–
1.
30
)
ve
rs
us
−
0.
38
(−
1.
02
to
0.
27
)
in
ct
rl
gp
.
Almutairi et al. BMC Geriatrics          (2020) 20:236 Page 3 of 19
Ta
b
le
1
St
ud
y
ch
ar
ac
te
ris
tic
s
of
th
e
in
cl
ud
ed
st
ud
ie
s
(C
on
tin
ue
d)
St
ud
y
ID
A
ut
ho
r
Ye
ar
C
ou
nt
ry
D
es
ig
n
Se
tt
in
g
Sa
m
pl
e
si
ze
A
ge
In
te
rv
en
tio
n
Fo
llo
w
-
up
O
ut
co
m
es
Su
m
m
ar
y
of
re
su
lts
re
si
de
nt
’s
G
P
be
fo
re
ca
se
co
nf
er
en
ce
.
9
C
ro
tt
y
et
al
.
(b
)
[2
5]
20
04
A
us
tr
al
ia
RC
T
lo
ng
-t
er
m
ca
re
fa
ci
lit
y/
ho
sp
ita
l
di
sc
ha
rg
e
N
H
=
85
N
H
R
=
11
0
D
is
ch
ar
ge
d
fro
m
3
ho
sp
ita
ls
65 an
d
ol
de
r
-p
ha
rm
ac
is
t
tr
an
si
tio
n
co
or
di
na
to
r
tr
an
sf
er
s
th
e
m
ed
ic
at
io
n-
re
la
te
d
in
fo
r-
m
at
io
n
to
th
e
fa
m
ily
ph
ys
ic
ia
n
an
d
co
m
m
un
ity
ph
ar
m
ac
is
t.
-c
as
e
co
nf
er
en
ce
at
fa
ci
lit
y
w
ith
in
m
on
th
of
tr
an
sf
er
in
cl
ud
e
ph
ar
m
ac
is
t,
nu
rs
e,
fa
m
ily
ph
ys
ic
ia
n,
co
m
m
un
ity
ph
ar
m
ac
is
t,
8
w
ee
ks
-M
A
Is
co
re
-H
os
pi
ta
l
ad
m
is
si
on
-M
ed
ic
at
io
n
re
la
te
d
pr
ob
le
m
s
-A
D
Es
,
-fa
lls
-N
o
ch
an
ge
in
M
A
Is
co
re
in
In
t
gp
2.
5,
95
%
C
I1
.4
–3
.7
)
-In
ct
rl
gp
M
A
Is
co
re
ha
d
w
or
se
ne
d
6.
5,
95
%
C
I3
.9
–9
.1
)
10
C
ro
tt
y
et
al
.
(c
)
[2
6]
20
04
A
us
tr
al
ia
RC
T
Re
si
de
nt
ia
l
ca
re
fa
ci
lit
ie
s
N
H
=
20
N
H
R
=
71
5
65 an
d
ol
de
r
-E
du
ca
tio
na
li
nt
er
ve
nt
io
n:
tw
o
(3
0
m
in
)
ou
tr
ea
ch
vi
si
ts
of
ph
ar
m
ac
is
ts
to
do
ct
or
s.
-
pr
es
en
tin
g
de
ta
ile
d
au
di
t
in
fo
rm
at
io
n
on
ps
yc
ho
tr
op
ic
us
e,
st
ro
ke
ris
k
re
du
ct
io
n,
an
d
fa
ll
ra
te
s.
−
4
(2
h
tr
ai
ni
ng
se
ss
io
ns
)
fo
r
lin
k
nu
rs
e
in
ea
ch
fa
ci
lit
y.
7 m
on
th
s
-M
A
Is
co
re
-H
os
pi
ta
l
ad
m
is
si
on
s
-
M
RP
-N
o
si
gn
ifi
ca
nt
di
ffe
re
nc
e
in
ps
yc
ho
tr
op
ic
dr
ug
us
e
be
fo
re
&a
ft
er
in
te
rv
en
tio
n
(0
.8
9,
95
%
C
I0
.6
9–
1.
15
).
-P
RN
of
an
tip
sy
ch
ot
ic
s
dr
ug
us
e
in
cr
ea
se
d
in
In
t
gp
co
m
pa
re
d
to
ct
rl
gp
(4
.9
5,
95
%
CI
1.
69
–1
4.
50
).
-
N
o
si
gn
ifi
ca
nt
di
ffe
re
nc
e
in
BZ
D
dr
ug
us
e
be
fo
re
&
af
te
r
in
te
rv
en
tio
n
(0
.8
9,
95
%
C
I0
.6
9–
1.
15
).
-
N
o
si
gn
ifi
ca
nt
di
ffe
re
nc
e
in
fa
lls
(1
.1
7,
95
%
C
I0
.8
6–
1.
58
).
11
Fo
ss
ey
et
al
.
[2
7]
20
06
U
K
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
12
N
H
R
=
34
9
65 an
d
ol
de
r
-T
ra
in
in
g
an
d
su
pp
or
t
to
ca
re
st
af
f
on
no
n-
ph
ar
m
ac
ol
og
ic
al
in
te
rv
en
tio
ns
,a
l-
te
rn
at
iv
es
to
ne
ur
ol
ep
tic
us
e.
-M
ed
ic
at
io
n
re
vi
ew
by
Le
d
by
ol
d
ag
e
ps
yc
hi
at
ris
t,
se
ni
or
nu
rs
e
ev
er
y
3
m
on
th
s
-c
on
ta
ct
be
tw
ee
n
ps
yc
hi
at
ris
t
an
d
pr
es
cr
ib
er
s
to
pr
ov
id
e
an
d
w
ro
te
pr
es
cr
ib
in
g
re
co
m
m
en
da
tio
ns
12 m
on
th
s
-P
ro
po
rt
io
n
of
re
si
de
nt
s
re
ce
iv
in
g
ne
ur
ol
ep
tic
s.
-C
M
A
I
-
Q
oL
-
re
du
ct
io
n
in
ne
ur
ol
ep
tic
us
e/
re
si
de
nt
(1
9.
1,
95
%
C
I0
.5
–3
7.
7%
,P
=
0.
04
5)
--
N
eu
ro
le
pt
ic
us
e
de
cr
ea
se
24
%
in
ex
p.
(4
7
to
23
%
)
bu
t
in
cr
ea
se
d
in
ct
rl
7.
6%
(4
9.
7
to
42
.1
%
).
-N
o
si
gn
ifi
ca
nt
ch
an
ge
s
in
C
M
A
I
12
Ze
rm
an
sk
y
et
al
.[
28
]
20
06
U
K
RC
T
N
ur
si
ng
ho
m
es
an
d
re
si
de
nt
ia
l
ho
m
es
N
H
=
65
N
H
R
=
66
1
65 an
d
ol
de
r
-
Ph
ar
m
ac
is
t
m
ed
ic
at
io
n
re
vi
ew
by
us
in
g
th
e
re
si
de
nt
’s
m
ed
ic
al
re
co
rd
.
-
co
ns
ul
ta
tio
n
w
ith
th
e
re
si
de
nt
’s
an
d
ca
re
r.
-p
ha
rm
ac
is
t
fo
rw
ar
d
w
rit
te
n
re
co
m
m
en
da
tio
ns
to
G
P.
6 m
on
th
s
-n
o.
of
ch
an
ge
s
in
m
ed
ic
at
io
n/
pa
tie
nt
-H
os
pi
ta
l
ad
m
is
si
on
s
-M
ed
ic
at
io
n-
re
la
te
d
pr
ob
le
m
s
-M
ed
ic
in
e
co
st
s
-N
um
be
r
of
m
ed
ic
in
es
pe
r
pa
rt
ic
ip
an
t
-
M
or
ta
lit
y
-
Fa
lls
-
SM
M
SE
-B
ar
th
el
in
de
x
-G
P
co
ns
ul
ta
tio
ns
-
In
cr
ea
se
in
m
ea
n
nu
m
be
r
of
dr
ug
ch
an
ge
s/
pa
tie
nt
ct
rl:
2.
4
ve
rs
us
3.
1
in
In
t
(P
<
0.
01
)
-n
o
of
fa
lls
re
du
ce
d
si
gn
ifi
ca
nt
ly
-
ph
ar
m
ac
is
t
re
co
m
m
en
da
tio
ns
ac
ce
pt
ed
(7
5.
6%
),
an
d
76
.6
%
of
th
es
e
re
co
m
m
en
da
tio
ns
w
er
e
im
pl
em
en
te
d.
13
G
ur
w
itz
20
08
U
SA
C
lu
st
er
Tw
o
la
rg
e
Fa
ci
lit
y
=
2
65
-C
om
pu
te
r
pr
og
ra
m
(o
rd
er
en
tr
y
w
ith
1
ye
ar
in
-N
um
be
r
of
-N
on
e
Almutairi et al. BMC Geriatrics          (2020) 20:236 Page 4 of 19
Ta
b
le
1
St
ud
y
ch
ar
ac
te
ris
tic
s
of
th
e
in
cl
ud
ed
st
ud
ie
s
(C
on
tin
ue
d)
St
ud
y
ID
A
ut
ho
r
Ye
ar
C
ou
nt
ry
D
es
ig
n
Se
tt
in
g
Sa
m
pl
e
si
ze
A
ge
In
te
rv
en
tio
n
Fo
llo
w
-
up
O
ut
co
m
es
Su
m
m
ar
y
of
re
su
lts
et
al
.[
29
]
an
d
C
an
ad
a
RC
T
lo
ng
-t
er
m
ca
re
fa
ci
lit
ie
s.
Re
si
de
nt
s=
11
18
an
d
ol
de
r
cl
in
ic
al
de
ci
si
on
su
pp
or
t
sy
st
em
).
-
m
or
e
th
an
60
0
po
te
nt
ia
lly
se
rio
us
dr
ug
-d
ru
g
in
te
ra
c-
tio
ns
al
er
ts
w
er
e
re
vi
ew
ed
.
-n
o
of
A
D
Es
w
er
e
id
en
tif
ie
d
(p
re
ve
nt
ab
le
ev
en
ts
in
cl
ud
in
g
er
ro
rs
an
d
dr
ug
-d
ru
g
in
te
ra
ct
io
ns
w
er
e
de
te
rm
in
ed
).
-a
le
rt
s
in
cl
ud
ed
in
th
e
C
D
SS
s
w
er
e
as
se
ss
ed
to
de
te
rm
in
e
if
an
y
of
th
em
co
ul
d
ha
ve
pr
ev
en
te
d
th
e
pr
es
cr
ib
in
g
of
th
es
e
dr
ug
s.
on
e
fa
ci
lit
y
an
d
6
m
on
th
s
in
th
e
ot
he
r
pr
ev
en
ta
bl
e
A
D
Es
-
A
D
Es
se
ve
rit
y
-
A
D
Es
pr
ev
en
ta
bi
lit
y
A
D
Es
=
(1
.0
6,
95
%
C
I0
.9
2–
1.
23
)
Pr
ev
en
ta
bl
e
A
D
Es
=
(1
.0
2,
95
%
C
I0
.8
1–
1.
30
)
14
Fi
el
d
et
al
.
[3
0]
20
09
C
an
ad
a
C
lu
st
er
RC
T
lo
ng
-t
er
m
ca
re
fa
ci
lit
y
-O
ne
lo
ng
-
te
rm
ca
re
Fa
ci
lit
y
-
22
lo
ng
-
st
ay
un
its
Re
si
de
nt
s=
83
3
65 an
d
ol
de
r
Th
e
22
lo
ng
-s
ta
y
un
its
w
er
e
ra
nd
om
ly
as
si
gn
ed
-
fo
r
In
te
rv
en
tio
n
un
its
’p
re
sc
rib
er
:A
le
rt
s
re
la
te
d
to
m
ed
ic
at
io
n
pr
es
cr
ib
in
g
fo
r
re
si
de
nt
s
w
ith
re
na
li
ns
uf
fic
ie
nc
y
w
er
e
di
sp
la
ye
d.
-C
on
tr
ol
un
its
:A
le
rt
s
hi
dd
en
an
d
tr
ac
ke
d
-
Th
e
ty
pe
s
al
er
ts
w
er
e:
m
ax
im
um
re
co
m
m
en
de
d
da
ily
do
se
/f
re
qu
en
cy
of
ad
m
in
is
tr
at
io
n,
m
ed
ic
at
io
n
to
be
av
oi
de
d,
an
d
m
is
si
ng
in
fo
rm
at
io
n.
12 m
on
th
s
-P
ro
po
rt
io
n
of
fin
al
dr
ug
or
de
rs
al
er
t
th
at
w
er
e
ap
pr
op
ria
te
-A
pp
ro
pr
ia
te
fin
al
dr
ug
or
de
rs
pr
op
or
tio
n
w
er
e
hi
gh
in
In
t
(1
.2
,9
5%
C
I
1.
0–
1.
4)
fo
r
fre
qu
en
cy
.
-fo
r
dr
ug
s
th
at
sh
ou
ld
be
av
oi
de
d
(2
.6
,
95
%
C
I1
.4
–5
.0
).
fo
r
m
is
si
ng
in
fo
rm
at
io
n
(1
.8
,9
5%
C
I1
.1
to
3.
4)
.
-A
pp
ro
pr
ia
te
fin
al
dr
ug
or
de
rs
Si
gn
ifi
ca
nt
in
In
t
(1
.2
95
%
C
I1
.0
–1
.4
).
15
Pa
tt
er
so
n
et
al
.[
31
]
20
10
Ire
la
nd
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
11
N
H
R
=
33
4
65 an
d
ol
de
r
-in
te
rv
en
tio
n
ho
m
es
w
er
e
vi
si
te
d
m
on
th
ly
by
tr
ai
ne
d
ph
ar
m
ac
is
ts
fo
r
1
ye
ar
.R
es
id
en
t’s
in
fo
rm
at
io
n
w
as
co
lle
ct
ed
fro
m
re
co
rd
s,
G
P
an
d
co
m
m
un
ity
ph
ar
m
ac
is
t.
In
te
rv
ie
w
s
w
er
e
co
nd
uc
te
d
w
ith
th
e
re
si
de
nt
s
an
d
ne
xt
of
ki
n
to
as
se
ss
th
e
ne
ed
fo
r
m
ed
ic
in
es
.
-
ap
pl
ie
d
an
al
go
rit
hm
to
as
se
ss
ap
pr
op
ria
te
ne
ss
of
ps
yc
ho
ac
tiv
e
m
ed
ic
at
io
n
an
d
w
or
ke
d
w
ith
G
Ps
to
im
pr
ov
e
th
e
pr
es
cr
ib
in
g
of
th
es
e
m
ed
ic
at
io
ns
.
M
on
th
ly
fo
r
12
m
on
th
s
-P
ro
po
rt
io
n
of
re
si
de
nt
s
pr
es
cr
ib
ed
in
ap
pr
op
ria
te
ps
yc
ho
ac
tiv
e
m
ed
ic
at
io
ns
.
-n
o
of
fa
lls
-
A
t
12
m
on
th
s,
re
si
de
nt
s
ta
ki
ng
in
ap
pr
op
ria
te
ps
yc
ho
ac
tiv
e
m
ed
ic
at
io
ns
in
In
t
gp
(1
9.
5%
)d
ec
re
as
ed
co
m
pa
re
d
to
ct
rl
gp
(5
0%
)
in
te
rv
en
tio
n
ho
m
es
(0
.2
6,
95
%
C
I0
.1
4–
0.
49
)
-N
o
ch
an
ge
th
e
fa
lls
ra
te
16
Te
st
ad
et
al
.
[3
2]
20
10
N
or
w
ay
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
4
N
H
R
=
21
1
65 an
d
ol
de
r
-E
du
ca
tio
n
an
d
tr
ai
ni
ng
pr
og
ra
m
(2
da
ys
se
m
in
ar
an
d
m
on
th
ly
gr
ou
p
gu
id
an
ce
fo
r
si
x
m
on
th
s)
.
12 m
on
th
s
-%
of
re
si
de
nt
s
us
in
g
an
tip
sy
ch
ot
ic
dr
ug
s
-
Re
st
ra
in
t
us
e
-N
o
st
at
ic
al
ly
si
gn
ifi
ca
nt
di
ffe
re
nc
e
in
an
tip
sy
ch
ot
ic
us
e.
-
Si
gn
ifi
ca
nt
re
du
ct
io
n
in
A
gg
re
ss
io
n
in
In
t
gp
at
6
&
12
m
on
th
fo
llo
w
-u
p.
-S
ig
ni
fic
an
t
re
du
ct
io
n
in
pr
op
or
tio
n
of
re
si
de
nt
s
re
st
ra
in
ed
at
6
m
on
th
s
bu
t
no
t
at
12
m
on
th
s.
Almutairi et al. BMC Geriatrics          (2020) 20:236 Page 5 of 19
Ta
b
le
1
St
ud
y
ch
ar
ac
te
ris
tic
s
of
th
e
in
cl
ud
ed
st
ud
ie
s
(C
on
tin
ue
d)
St
ud
y
ID
A
ut
ho
r
Ye
ar
C
ou
nt
ry
D
es
ig
n
Se
tt
in
g
Sa
m
pl
e
si
ze
A
ge
In
te
rv
en
tio
n
Fo
llo
w
-
up
O
ut
co
m
es
Su
m
m
ar
y
of
re
su
lts
17
La
pa
ne
et
al
.[
33
]
20
11
U
ni
te
d
St
at
es
C
lu
st
er
RC
T
N
ur
si
ng
ho
m
es
N
H
=
25
N
H
R
=
33
21
65 an
d
ol
de
r
-
G
RA
M
is
au
to
m
at
ic
al
ly
ge
ne
ra
te
d
to
as
si
st
co
ns
ul
ta
nt
ph
ar
m
ac
is
ts
id
en
tif
y
re
si
de
nt
s
at
ris
k
fo
r
de
lir
iu
m
/
fa
lls
-D
et
ai
le
d
in
st
ru
ct
io
n
of
co
ns
ul
ta
nt
ph
ar
m
ac
is
ts
pr
ov
id
in
g
ta
rg
et
ed
m
ed
ic
at
io
n
re
vi
ew
fo
r
al
l
re
si
de
nt
s
at
hi
gh
-r
is
k.
-
Re
po
rt
s
w
ith
in
24
h
of
ad
m
is
si
on
an
d
us
ed
du
rin
g
m
on
th
ly
re
vi
ew
.
12 m
on
th
s
−
M
or
ta
lit
y
−
H
os
pi
ta
l
ad
m
is
si
on
po
te
nt
ia
lly
du
e
to
A
D
Es
.
-M
or
ta
lit
y
ra
te
/1
00
0
re
si
de
nt
-m
on
th
s,
H
R:
0.
90
(a
dj
us
te
d
H
R
0.
89
,9
5%
C
I0
.7
3–
1.
08
)
-H
os
pi
ta
la
dm
is
si
on
/1
00
0
re
si
de
nt
-m
on
th
s,
H
R:
1.
13
(a
dj
us
te
d
H
R
1.
11
,9
5%
C
I0
.9
4–
1.
31
).
18
Po
pe
et
al
.
[3
4]
20
11
U
K,
Ire
la
nd
RC
T
N
ur
se
-
m
an
ag
ed
co
nt
in
ui
ng
-
ca
re
N
H
R
=
10
nu
rs
e-
m
an
ag
ed
co
nt
in
ui
ng
-
ca
re
Re
si
de
nt
s=
22
5
65 an
d
ol
de
r
-m
ed
ic
al
as
se
ss
m
en
t
by
a
ge
ria
tr
ic
ia
n,
an
d
us
in
g
Be
er
’s
cr
ite
ria
fo
r
m
ul
tid
is
ci
pl
in
ar
y
pa
ne
lm
ed
ic
at
io
n
re
vi
ew
.
-
re
co
m
m
en
da
tio
ns
fo
rw
ar
de
d
to
th
e
G
P.
-
af
te
r
6
m
on
th
s,
re
as
se
ss
m
en
t
oc
cu
rr
ed
6 m
on
th
s
-n
o
of
dr
ug
s
pr
es
cr
ib
ed
-m
or
ta
lit
y
-m
ed
ic
at
io
n
co
st
−
92
.7
%
of
pa
tie
nt
s
re
ce
iv
ed
m
ed
ic
at
io
n
re
co
m
m
en
da
tio
ns
an
d
80
.1
%
ac
ce
pt
ed
.
-
to
ta
ln
um
be
r
of
m
ed
ic
at
io
ns
/
pa
tie
nt
/d
re
du
ce
d
in
In
t
gp
(1
1.
64
–1
1.
09
co
m
pa
re
d
to
ct
rl
11
.0
7–
11
.5
).
19
Ke
rs
te
n
et
al
.[
35
]
20
13
N
or
w
ay
RC
T
N
ur
si
ng
ho
m
es
N
H
=
22
N
H
R
=
87
65 an
d
ol
de
r
-A
pa
pe
r-
ba
se
d
re
vi
ew
w
ith
a
vi
ew
to
re
du
ce
A
D
S
sc
or
es
w
er
e
co
nd
uc
te
d
by
cl
in
ic
al
ph
ar
m
ac
is
t.
-c
lin
ic
al
ph
ar
m
ac
is
t
di
sc
us
s
di
sc
on
tin
ue
or
re
pl
ac
e
an
an
tic
ho
lin
er
gi
c
dr
ug
w
ith
th
e
ph
ys
ic
ia
n
be
fo
re
ch
an
ge
s
w
er
e
im
pl
em
en
te
d.
8
w
ee
ks
-
C
og
ni
tiv
e
fu
nc
tio
n
-
an
ti-
ch
ol
in
er
gi
c
si
de
-e
ffe
ct
s
-
co
gn
iti
ve
fu
nc
tio
n
no
t
im
pr
ov
ed
-
an
ti-
ch
ol
in
er
gi
c
si
de
-e
ffe
ct
s
no
t
im
pr
ov
ed
20
M
ilo
s
et
al
.
[3
6]
20
13
Sw
itz
er
la
nd
RC
T
N
ur
si
ng
ho
m
es
or
co
m
m
un
ity
N
H
R
=
27
9
75 ye
ar
s
or ol
de
r
Ph
ar
m
ac
is
ts
-le
d
m
ed
ic
at
io
n
re
vi
ew
th
at
in
cl
ud
ed
as
se
ss
m
en
t
of
re
le
va
nt
pa
rt
s
of
(E
M
Rs
)
an
d
co
lle
ct
io
n
of
pa
tie
nt
’s
bl
oo
d
sa
m
pl
e
da
ta
.
-
cl
in
ic
al
ph
ar
m
ac
is
t-
in
iti
at
ed
m
ed
ic
at
io
n
re
vi
ew
s
ba
se
d
on
th
e
ba
ck
gr
ou
nd
in
fo
rm
at
io
n
to
id
en
tif
y
D
RP
s.
2 m
on
th
s
-
no
of
PI
M
s.
-
D
RP
s
−
6%
de
cr
ea
se
d
in
PI
M
in
In
t
gp
-T
ot
al
no
of
D
RP
s
in
th
e
in
te
rv
en
tio
n
gr
ou
p
w
as
43
1
[m
ea
n
2.
5
(1
.5
)/
pa
tie
nt
(ra
ng
e
0–
9)
-
N
o
si
gn
ifi
ca
nt
di
ffe
re
nc
e
be
tw
ee
n
th
e
no
of
D
RP
s
in
nu
rs
in
g
ho
m
e
pa
tie
nt
s
[m
ea
n
2.
53
(1
.3
3)
]
an
d
co
m
m
un
ity
-
dw
el
lin
g
pa
tie
nt
s
[m
ea
n
2.
55
(1
.2
9)
]
Si
gn
ifi
ca
nt
in
ch
an
ge
s
in
th
e
ac
tio
ns
ta
ke
n
by
th
e
ph
ys
ic
ia
n
w
er
e
fo
r
lo
w
er
ed
do
sa
ge
.
21
Fr
an
ke
nt
ha
l
et
al
.[
37
]
20
14
Is
ra
el
RC
T
ch
ro
ni
c
ca
re
ge
ria
tr
ic
fa
ci
lit
y
N
H
=
1
N
H
R
=
35
9
65 an
d
ol
de
r
-m
ed
ic
at
io
n
re
vi
ew
co
nd
uc
te
d
by
ph
ar
m
ac
is
t
-t
o
id
en
tif
y
PI
M
s
an
d
PP
O
s
m
ed
ic
at
io
ns
sc
re
en
ed
w
ith
ST
O
PP
/
ST
A
RT
cr
ite
ria
th
en
fo
llo
w
ed
up
w
ith
re
co
m
m
en
da
tio
ns
to
th
e
ch
ie
f
ph
ys
ic
ia
n.
-
ch
ie
fp
hy
si
ci
an
de
ci
de
d
to
ac
ce
pt
or
no
t.
12 M
on
th
s
-m
ed
ic
at
io
n
ap
pr
op
ria
te
ne
ss
-m
or
ta
lit
y
-h
os
pi
ta
l
ad
m
is
si
on
-Q
oL
-M
RP
-m
ed
ic
at
io
n
co
st
-s
ig
ni
fic
an
t
de
cr
ea
se
d
in
th
e
av
er
ag
e
nu
m
be
r
of
dr
ug
s
pr
es
cr
ib
ed
in
In
t
gp
(P
<
.0
01
).
-
si
gn
ifi
ca
nt
de
cr
ea
se
d
in
th
e
av
er
ag
e
nu
m
be
r
of
fa
lls
in
In
t
gp
(P
=
.0
06
).
-d
ec
re
as
e
in
th
e
av
er
ag
e
dr
ug
co
st
s
in
In
t
gp
by
U
S$
29
.
-
ho
sp
ita
liz
at
io
n,
FI
M
sc
or
es
,a
nd
Q
oL
w
er
e
sa
m
e
in
bo
th
gr
ou
ps
.
22
G
ar
cí
a-
G
ol
la
rt
e,
et
al
.[
38
]
20
14
Sp
ai
n
C
lu
st
er
-
RC
T
N
ur
si
ng
ho
m
es
N
H
=
36
N
H
R
=
71
6
65 an
d
ol
de
r
−
30
do
ct
or
s
re
ce
iv
ed
ed
uc
at
io
na
l
in
te
rv
en
tio
n.
-
Th
e
ed
uc
at
io
na
li
nt
er
ve
nt
io
n
in
cl
ud
ed
ge
ne
ra
ld
ru
g
us
e
in
el
de
rly
,S
TO
PP
6 M
on
th
s
-
M
ed
ic
at
io
n
ap
pr
op
ria
te
ne
ss
(S
TO
PP
-S
TA
RT
)
-H
os
pi
ta
l
-
Th
e
m
ea
n
nu
m
be
r
of
in
ap
pr
op
ria
te
dr
ug
s
w
as
hi
gh
er
in
ct
rl
gp
(1
.2
9–
1.
56
)
co
m
pa
re
d
to
In
t
gp
(0
.8
1–
1.
13
).
-n
o
of
fa
lls
in
cr
ea
se
d
in
th
e
ct
rl
gp
fro
m
Almutairi et al. BMC Geriatrics          (2020) 20:236 Page 6 of 19
Ta
b
le
1
St
ud
y
ch
ar
ac
te
ris
tic
s
of
th
e
in
cl
ud
ed
st
ud
ie
s
(C
on
tin
ue
d)
St
ud
y
ID
A
ut
ho
r
Ye
ar
C
ou
nt
ry
D
es
ig
n
Se
tt
in
g
Sa
m
pl
e
si
ze
A
ge
In
te
rv
en
tio
n
Fo
llo
w
-
up
O
ut
co
m
es
Su
m
m
ar
y
of
re
su
lts
ST
A
RT
w
or
ks
ho
p,
an
d
ad
ve
rs
e
dr
ug
re
ac
tio
ns
in
ol
de
r
pe
op
le
.
-p
ar
tic
ip
an
ts
al
so
re
ce
iv
ed
ed
uc
at
io
na
l
m
at
er
ia
la
nd
re
fe
re
nc
es
-
on
-d
em
an
d
su
pp
or
t
(v
ia
ph
on
e)
fo
r
6
m
on
th
s
pr
ov
id
ed
by
th
e
ed
uc
at
or
.
ad
m
is
si
on
s
M
ed
ic
at
io
n
ap
pr
op
ria
te
ne
ss
(S
TO
PP
-S
TA
RT
)
-F
al
ls
19
.3
–2
8%
an
d
no
t
si
gn
ifi
ca
nt
ly
ch
an
ge
in
th
e
in
te
rv
en
tio
n
gr
ou
p
fro
m
25
.3
–
23
.9
%
.
23
Pi
tk
al
a
et
al
.
[3
9]
20
14
Fi
nl
an
d
C
lu
st
er
-
RC
T
A
ss
is
te
d
liv
in
g
fa
ci
lit
ie
s
Fa
ci
lit
y
=
20
Re
si
de
nt
s=
22
7
65 an
d
ol
de
r
-t
w
o
4-
h
in
te
ra
ct
iv
e
tr
ai
ni
ng
se
ss
io
ns
fo
r
nu
rs
in
g
st
af
f
ai
m
ed
to
en
ab
le
nu
rs
es
to
re
co
gn
iz
e
po
te
nt
ia
lly
ha
rm
fu
lm
ed
ic
a-
tio
ns
an
d
co
rr
es
po
nd
in
g
ad
ve
rs
e
dr
ug
ev
en
ts
.
-t
he
se
co
nd
4-
h
se
ss
io
ns
:c
as
e-
st
ud
y-
ba
se
d.
-
nu
rs
es
in
th
is
in
te
rv
en
tio
n
w
er
e
as
ke
d
to
id
en
tif
y
po
te
nt
ia
lM
D
R
an
d
hi
gh
lig
ht
th
es
e
to
th
e
co
ns
ul
tin
g
do
ct
or
.
12 m
on
th
s
-M
ed
ic
at
io
n
ap
pr
op
ria
te
ne
ss
-H
os
pi
ta
l
ad
m
is
si
on
s
-M
or
ta
lit
y
-Q
oL
-M
M
SE
-m
ea
n
nu
m
be
r
of
po
te
nt
ia
lly
ha
rm
fu
l
dr
ug
s
lo
w
er
ed
in
in
t
gp
(−
0.
43
,9
5%
C
I-
0.
71
to
−
0.
15
)
an
d
no
t
ch
an
ge
d
in
ct
rl
gp
(+
0.
11
,9
5%
C
I−
0.
09
to
+
0.
31
)
(P
=
.0
04
).
-H
R
Q
oL
de
cr
ea
se
d
in
In
t
gp
(−
0.
03
8,
95
%
C
I−
0.
05
4
to
−
0.
02
2)
co
m
pa
re
d
to
ct
rl
gp
(−
0.
07
2,
95
%
C
I−
0.
08
9
to
−
0.
05
5)
(P
=
.0
05
).
-h
os
pi
ta
la
dm
is
si
on
de
cr
ea
se
d
si
gn
ifi
ca
nt
ly
in
in
t
gp
(1
.4
da
ys
/p
er
so
n/
ye
ar
,9
5%
C
I1
.2
to
−
1.
6)
co
m
pa
re
d
to
ct
rl
gp
(2
.3
da
ys
/p
er
so
n/
ye
ar
;9
5%
C
I
2.
1t
o
−
2.
7)
,R
R
=
0.
60
,9
5%
C
I0
.4
9
to
−
0.
75
,P
<
.0
01
).
24
C
on
no
lly
et
al
.[
40
]
20
15
N
ew
Ze
al
an
d
C
lu
st
er
-
RC
T
RA
CF
s
N
H
=
36
N
H
R
=
19
98
65 an
d
ol
de
r
-
G
er
on
to
lo
gy
nu
rs
e
sp
ec
ia
lis
t
de
liv
er
ed
st
af
f
ed
uc
at
io
n
an
d
cl
in
ic
al
co
ac
hi
ng
.
-
be
nc
hm
ar
ki
ng
of
re
si
de
nt
in
di
ca
to
rs
in
cl
ud
in
g
re
st
ra
in
t
us
e,
fa
lls
,e
tc
.).
-
m
ul
tid
is
ci
pl
in
ar
y
te
am
m
ee
tin
g
(1
h)
m
on
th
ly
fo
r
th
e
fir
st
3
m
on
th
s.
14 m
on
th
s
-
H
os
pi
ta
l
ad
m
is
si
on
s
(a
m
bu
la
to
ry
se
ns
iti
ve
ho
sp
ita
lis
at
io
ns
,
to
ta
la
cu
te
ad
m
is
si
on
s)
.
-M
or
ta
lit
y
-n
o
di
ffe
re
nc
es
be
tw
ee
n
In
t
an
d
ct
rl
gp
in
ra
te
s
of
am
bu
la
to
ry
se
ns
iti
ve
ho
sp
ita
lis
at
io
ns
ad
m
is
si
on
(1
.0
7;
95
%
C
I
0.
85
–1
.3
6;
P
=
0.
59
).
-n
o
di
ffe
re
nc
e
in
m
or
ta
lit
y
(1
.1
1;
95
%
C
I
0.
76
–1
.6
1;
P
=
0.
62
).
25
Po
tt
er
et
al
.
[4
1]
20
16
A
us
tr
al
ia
RC
T
RA
CF
S
Fa
ci
lit
y
=
4
Re
si
de
nt
s=
95
65 an
d
ol
de
r
-m
ed
ic
at
io
n
re
vi
ew
fo
llo
w
ed
by
di
sc
on
tin
ui
ng
no
n-
be
ne
fic
ia
lm
ed
ic
a-
tio
ns
co
nd
uc
te
d
by
a
G
P
an
d
a
ge
ria
tr
i-
ci
an
/c
lin
ic
al
Ph
ar
m
ac
ol
og
is
t
-
D
ur
in
g
de
pr
es
cr
ib
in
g,
th
e
G
P
re
vi
ew
ed
pa
rt
ic
ip
an
ts
w
ee
kl
y.
12 m
on
th
s
-n
o
of
fa
lls
-m
or
ta
lit
y
-n
o
of
fa
lle
rs
-c
og
ni
tiv
e
fu
nc
tio
n
-Q
oL
-m
or
ta
lit
y
26
%
in
in
t
gp
an
d
40
%
in
ct
rl
gp (H
R
0.
60
,9
5%
C
I0
.3
0
to
1.
22
).
-Q
oL
C
ha
ng
es
in
In
t
gp
(−
1.
0
±
4.
3)
co
m
pa
re
d
to
ct
rl
gp
(−
1.
0
±
4.
7)
.
-F
al
ls
-P
at
ie
nt
s
w
ith
on
e
or
m
or
e
fa
lls
in
in
t
gp
(0
.5
6,
95
%
C
I0
.4
2–
0.
69
)
co
m
pa
re
d
to
ct
rl
gp
(0
.6
5,
95
%
C
I0
.5
0–
0.
77
),
(p
=
0.
40
)
A
bb
re
vi
at
io
ns
:R
CT
Ra
nd
om
is
ed
C
on
tr
ol
le
d
Tr
ia
ls
,N
H
R
N
ur
si
ng
H
om
e
Re
si
de
nt
s,
N
H
s
N
ur
si
ng
H
om
es
,C
D
SS
s
C
om
pu
te
ris
ed
C
lin
ic
al
D
ec
is
io
n
Su
pp
or
t
Sy
st
em
s,
CI
C
on
fid
en
ce
In
te
rv
al
,G
P
G
en
er
al
Pr
ac
tit
io
ne
r,
no
nu
m
be
r,
m
in
m
in
ut
es
,h
r.
ho
ur
,A
Ps
A
nt
ip
sy
ch
ot
ic
s,
gp
gr
ou
p,
ct
rl
co
nt
ro
l,
In
t
in
te
rv
en
tio
n,
M
M
SE
M
in
i-M
en
ta
lS
ta
te
Ex
am
,G
D
S
G
er
ia
tr
ic
D
ep
re
ss
io
n
Sc
al
e,
BA
SD
EC
Br
ie
f
A
ss
es
sm
en
t
Sc
he
du
le
D
ep
re
ss
io
n
C
ar
ds
,C
RB
RS
C
ric
ht
on
-
Ro
ya
lB
eh
av
io
ur
Ra
tin
g
Sc
al
e,
P,
p
va
lu
e,
N
SA
ID
s
N
on
-S
te
ro
id
al
A
nt
i-I
nf
la
m
m
at
or
y
D
ru
gs
,A
D
Es
A
dv
er
se
D
ru
g
Ev
en
ts
,M
A
IM
ed
ic
at
io
n
A
pp
ro
pr
ia
te
ne
ss
In
de
x,
M
RP
M
ed
ic
at
io
n-
re
la
te
d
Pr
ob
le
m
,P
RN
pr
o
re
na
ta
(w
he
n
ne
ce
ss
ar
y)
,B
ZD
Be
nz
od
ia
ze
pi
ne
,C
M
A
IC
oh
en
-M
an
sf
ie
ld
A
gi
ta
tio
n
In
ve
nt
or
y,
Q
oL
Q
ua
lit
y
of
Li
fe
,e
xp
ex
pe
rim
en
t
gr
ou
p,
%
pe
rc
en
ta
ge
,G
RA
M
G
er
ia
tr
ic
Ri
sk
A
ss
es
sm
en
t
M
ed
G
ui
de
,H
R
H
az
ar
d
Ra
tio
,A
D
S
A
nt
ic
ho
lin
er
gi
c
D
ru
g
Sc
al
e,
EM
Rs
el
ec
tr
on
ic
m
ed
ic
al
re
co
rd
s,
PI
M
s
Po
te
nt
ia
lI
na
pp
ro
pr
ia
te
m
ed
ic
at
io
ns
,P
PO
s
po
te
nt
ia
lp
re
sc
rip
tio
n
om
is
si
on
s,
ST
O
PP
/S
TA
RT
Sc
re
en
in
g
To
ol
of
O
ld
er
Pe
rs
on
’s
po
te
nt
ia
lly
in
ap
pr
op
ria
te
Pr
es
cr
ip
tio
ns
an
d
Sc
re
en
in
g
To
ol
to
A
le
rt
do
ct
or
s
to
Ri
gh
t
Tr
ea
tm
en
t,
FI
M
Fu
nc
tio
na
lI
nd
ep
en
de
nc
e
M
ea
su
re
Almutairi et al. BMC Geriatrics          (2020) 20:236 Page 7 of 19
Background
Inappropriate medication prescription encompasses mis-
prescribing, overprescribing, and underprescribing. Mis-
prescribing involves the use of medication that
significantly increases the risk of adverse drug events
(ADEs) and involves incorrect dose, frequency, adminis-
tration and duration. Use of medications that are likely
to cause drug-drug interactions or drug-disease interac-
tions is also an aspect of misprescribing. Overprescribing
involves the use of medications without clear indica-
tions. Underprescribing is the omission of clinically-
indicated medication that may have potential benefit for
treatment of the disease [1].
Residents of aged care facilities (RACFs) are often frail
and have multiple comorbidities. On average RACF resi-
dents take more medications than younger age groups,
and more than community-dwelling elderly with similar
disease complications [2]. They are frequently prescribed
multiple medications that can increase the risk of ADEs,
morbidity and mortality [3, 4]. Moreover, the majority of
these residents have dementia and the use of psycho-
tropic drugs is typically high. Age-related changes in
pharmacodynamics and pharmacokinetics, multiple co-
morbidities, and the presence of polypharmacy are the
main factors often associated with ageing that makes op-
timisation of drug therapy a complex task. Furthermore,
Previous studies indicate that about 40% of prescrip-
tions for RACF residents may be suboptimal or inappro-
priate [5]. Consequently, there is a heightened risk of
adverse drug reactions (ADRs), hospitalisations, and
medical expense [3, 6]. Therefore, there is an urgent
need to improve prescribing and to optimise drug ther-
apy for older people living in care homes [5, 7].
Medication optimisation is a person-centred approach
designed to ensure medication safety and improved clin-
ical outcomes via effective use of medicine [8, 9]. A range
of interventions for optimisation of prescribed medica-
tions in RACFs have been developed to potentially opti-
mise prescribing. These include medication review,
education programs, the use of clinical decision support
technology, and multidisciplinary case-conferencing.
These interventions have been evaluated to determine the
effect of optimising prescribing in nursing homes and in
older people with dementia, but the results were not
pooled statistically [10–12], and the nursing home specific
data require updating. The 2011 review concluded that in
nursing homes, educational interventions including aca-
demic detailing seems to show most promise [12]. The
other 2011 review found that education and pharmacist
drug review may reduce inappropriate drug use under cer-
tain circumstances [11]. The other 2018 review of 18 ex-
perimental studies specific to older people living with
dementia in any setting concluded that the improvement
of medication appropriateness is supported by emerging
evidence, and the impact of these interventions on demen-
tia patients’ outcomes required more research [10].
We therefore aimed to systematically review the avail-
able interventions conducted by a health professional
that aimed to increase the appropriateness of medica-
tions used in residential aged care facilities and to evalu-
ate their effects on medication appropriateness and
residents’ clinical outcomes.
Methods
This systematic review was conducted and reported in com-
pliance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [13]. A
PRISMA checklist can be found in Additional file 1. The re-
view was registered with the international prospective regis-
ter of systematic reviews PROSPERO CRD42020148669.
Data sources and search strategy
An electronic search of the literature was conducted
from inception to May 2019 using the following data-
bases — MEDLINE, PubMed, Google scholar, Psy-
cINFO. A combination of the following keywords and
MeSH terms were used: “Optimize OR improve OR
maximize OR optimization AND medication OR drugs
OR medicines AND side effects OR safety OR adminis-
tration OR review AND nursing homes OR residential
OR aged care”. The reference lists of the relevant articles
and reviews were hand-searched to further identify any
additional studies. The complete search strategy is pre-
sented in Additional file 2.
Study selection
The title and abstract of all retrieved articles were ini-
tially reviewed to find those potentially relevant to the
study area. The abstract of the selected papers was
assessed against five inclusion criteria: (i) randomised
controlled trials (RCTs) and cluster randomised con-
trolled trials (cRCTs); (ii) residents’ age 60 and older;
settings are residential aged care facility or nursing
homes or residential continuing care hospitals; (iii) inter-
ventions to increase the appropriateness of medications
used in nursing homes (iv) reported in English; (v) pub-
lished between 1980 and 2019.
Data extraction and quality assessment
Details of the included articles were independently ex-
tracted by two authors (H.A, and L.F). Data included de-
tails of the authors, publication year, country, study
design, age, setting, sample size, intervention, follow-up,
outcomes, and summary of results. Table 1 depicts the
study characteristics of the included studies.
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Assessment of risk of Bias
The quality of each article and risk of bias were assessed
independently by the two reviewers (H.A, and L.F). For
assessing risk of bias we used the Cochrane Collabora-
tion’s tool [42]. The studies assessed based on standard
criteria: adequate sequence generation, allocation con-
cealment, blinding of participants and personnel, blind-
ing of outcome assessment, incomplete outcome data,
selective reporting, and other bias. Risk of bias tables
provided in RevMan v5.3 was used to assess reporting
Fig. 1 PRISMA flow diagram
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bias. See Risk of Bias in Included Studies Section (Figs. 2
and 3).
Statistical analysis
Outcome measures such as medication appropriateness,
hospitalisation, mortality and other outcomes were
assessed for heterogeneity and were pooled for meta-
analysis using fixed effects methods if little heterogeneity
was found or using random effects methods if hetero-
geneity was present (P value < .05). The software Review
Manager (RevMan) version 5.3 (The Cochrane Collabor-
ation, The Nordic Cochrane Centre, Copenhagen,
Denmark) was used. The risk ratios (RR) for dichotom-
ous outcomes with 95% confidence intervals (CIs) were
calculated. Heterogeneity was measured by I2. Continu-
ous outcomes were expressed as mean difference (MD)
and standardized mean difference (SMD) between
groups with a 95% confidence interval (95% CI). Funnel
plots were used to assess possible publication bias (Add-
itional file 3: Figs. S1 to S9). Effect estimates were con-
sidered statistically significant of the p value was less
than 0.05 (2 tailed).
Results
The literature search provided a total of 6024 potentially
relevant publications. Following independent screening
for eligibility, 106 articles were assessed for eligibility of
which 25 RCTs and cRCTs were included in this system-
atic review. The flowchart of the literature search is rep-
resented in Fig. 1.
Study design
The design consisted of 15 studies [14, 17, 19–24, 27,
29–33, 38–40] comprising five cRCTs and 10 RCTs [15,
16, 25, 26, 28, 34–37, 41].
Country and settings
Trials in residential aged care settings or residential con-
tinuing care hospitals (long-term care) were conducted
in the USA (n = 5) [14–16, 22, 33], Australia (n = 5) [23–
26, 41], UK (n = 3) [21, 27, 28], Norway (n = 2) [32, 35],
and one each in Canada [30], Israel [37], Sweden (4 pa-
pers reported results of one) [17–20], Finland [39], Spain
[38], Switzerland [36], Ireland [31], New Zealand [40]
and one combined between USA and Canada [29] and
one combined between UK and Ireland [34].
Participants
Studies included involved older people living in residen-
tial aged care facilities aged 60 years and older with a
mean age range of 81.2 to 87.2 years.
Interventions
Various interventions applied by pharmacist, physician
or a multidisciplinary team (physicians, pharmacists, and
nurses) in the included studies were evaluated. Methods
to review residents’ medications were presented in 12
studies [21, 23, 25, 28, 31, 33–38, 41]; nine studies [14–
16, 22, 26, 27, 32, 39, 40] investigated the impact of staff
education, four studies [17, 20, 24, 25, 40] evaluated the
implementation of multi-disciplinary case conferencing,
and two studies [29, 30] evaluated computerised clinical
decision support systems.
Outcomes
Most outcome measures in the reviewed studies were re-
ported as (a) medication appropriateness (n = 16) [14–
17, 19, 23–27, 30, 31, 35–39], hospital admission (n =
11) [21, 23, 25, 28, 33, 34, 37–41], mortality (n = 9) [21–
23, 28, 33, 34, 37, 39, 40], medication-related problems
(n = 7) [18, 20, 21, 23, 25, 28, 36, 37], falls (n = 7) [26–
28, 31, 33, 38, 41], quality of life (n = 5) [27, 34, 37, 39,
41], Behavioural and Psychological Symptoms of De-
mentia BPSD (n = 4) [15, 16, 27, 32], ADEs (n = 2) [25,
29], and cognitive function (n = 2) [15, 35].
Medication appropriateness
Medication appropriateness was assessed in 11,470 resi-
dents encompassing 16 RCTs [14–17, 19, 23–27, 30, 31,
35–39] by different tools including Medication Appropri-
ateness Index (MAI) [24–26], STOPP-START criteria [37,
38], indicators of appropriate neuroleptic prescribing in
nursing homes [27], Beers criteria, Anticholinergic Drug
Score (ADS), number of psychotropic medications and
non-steroidal anti-inflammatory drugs (NSAIDs( [39].
Other outcomes
Hospital admission
Eleven studies [21, 23, 25, 28, 33, 34, 37–41] specified
hospital admission as an outcome measure. Furniss et al.
[21] reported in-patient days as hospital admission. Rob-
erts et al. [23] investigated the proportion of hospitalised
residents. Crotty et al. [25] reported hospital usage based
on unplanned visits to emergency department and hos-
pital readmission. Zermansky et al. [28] reported hospi-
talisation rate during a 6-month period per resident.
Lapane et al. [33] investigated any hospitalisation and
potential ADE-related hospitalisation in a randomised
cluster trial. Pope et al. [34] reported the number of
admissions to acute hospital. Frankenthal et al. [37]
reported hospital admissions. Garcia-Gollarte et al.
[38] reported the total number of days spent in hos-
pital. Pitkala et al. [39] reported hospital days/resi-
dent/year. Connolly et al. [40] reported all acute
admissions and ambulatory sensitive hospitalisations.
Potter et al. [41] reported hospital admission as the
Almutairi et al. BMC Geriatrics          (2020) 20:236 Page 10 of 19
proportion of residents experiencing an unplanned
hospital admission.
Mortality
Nine studies [21–23, 28, 33, 34, 37, 39, 40] included
mortality as an outcome measure. Furniss et al. [21] re-
ported mortality as a number of deaths over 8-months,
by Zermansky et al. [28] over 6-months. The number of
deaths was reported by Stein et al. [22] over a 3-month
evaluation period, by Pope et al. [34] over a 6-month
period, and by Frankenthal et al. [37] over 1 year. Rob-
erts et al. [23] reported residents’ cumulative survival
and death proportion for 1 year. Lapane et al. [33] calcu-
lated the average percentage of mortality per 1000
person-months. Pitkala et al. [39] used a Cox propor-
tional hazard model to calculate hazard ratios. Connolly
et al. [40] reported death risk ratio over 14 months.
Falls
Seven studies [26–28, 31, 33, 38, 41] included falls as an
outcome measure. Crotty et al. [26] calculated the per-
centage of residents who fell in 3 months prior. Fossey
et al. [27] reported the proportion of residents who had
at least one fall over a 12-month period. Zermansky
et al. [28] reported number of falls over 6 months. Pat-
terson et al. [31] calculated falls rate per 100 resident-
months. Lapane et al. [33] reported the number of
people falling over 12 months. Garcia-Gollarte et al. [38]
reported the number of falls and fallers post-
intervention. Potter et al. [41] reported the proportion of
patients with one or more falls.
Medication - related problems
Seven studies [18, 20, 21, 23, 25, 28, 36, 37] included
medication - related problems as an outcome measure.
Claesson and Schmidt et al. [18, 20] reported the type and
frequency of drug-related problems discussed by clinical
teams and their recommendations. Furniss et al. [21] re-
ported the total number of recommendations made by the
pharmacist, and the accepted recommendations by the
general physician (GP) and the actual changes in medica-
tions. Roberts et al. [23] calculated the number of drug
changes. Crotty et al. [25] categorised medication-related
problems to different categories such as high dose, admin-
istration time and no indication. Zermansky et al. [28]
measured the recommendations made by the pharmacist
against the number of accepted/rejected recommenda-
tions of the doctor. Milos et al. [36] measured the percent-
age of medications changed. Frankenthal et al. [37]
measured the number of recommendations accepted by
the GP according to the STOPP-START criteria. There
was no extractable data for this outcome and therefore
meta-analysis was not performed.
Quality of Life (QoL)
Five studies [27, 34, 37, 39, 41] reported patient Quality
of Life (QoL). Fossey et al. [27] reported rating for well-
being in residents. Pope et al. [34] measured QoL by
asking patients with Abbreviated Mental Test Score
(AMTS ≥8) or staff who were familiar with the patient
about whether the intervention had been of benefit.
Frankenthal et al. [37] used the Medical Outcomes Study
12-item Short-form Health survey (SF-12). Pitkala et al.
[39] used the 15-dimensional instrument of health-
related QoL (15D). Potter et al. [41] used self-reported
QoL assessed with Quality of Life in Alzheimer’s De-
mentia (QOLAD).
Behavioural and Psychological Symptoms of Dementia
(BPSD)
Four studies [15, 16, 27, 32] assessed Behavioural and
Psychological Symptoms of Dementia (BPSD). Rovner
et al. [15] reported behaviour disorder. Fossey et al. [27]
reported aggression events in past 12 months and Testad
et al. [32] used the Cohen-Mansfield agitation inventory
tool (CMAI) to measure agitated behaviour of residents.
Meador et al. [16] used Nursing Home Behaviour Prob-
lem Scale (NHBPS).
Fig. 2 Risk of bias graph
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ADEs
Two studies [25, 29] reported ADEs. One study defined
ADE as an injury resulting from the use of a drug [29].
Crotty et al. [25] investigated number of ADEs during
the 8-week follow-up period.
Cognitive function
Two studies [15, 35] included cognitive function as an
outcome measure. Rovner et al. [15] used the Norwegian
version of the global cognitive test Mini-Mental Sate
Examination (MMSE) to assess cognition. Kersten et al.
[35] used the Consortium to Establish a Registry for Alz-
heimer’s Disease (CERAD)‘s 10-word list test for delayed
recall and recognition and MMSE.
Risk of bias in included studies
Assessment of the risk of bias is summarised in (Figs. 2
and 3). Except for nine studies with unclear risk [14, 16,
17, 19, 20, 22, 32, 35, 37], the remaining 16 studies had
low risk of selection bias. Performance bias was high in
21 (77.8%) studies [15, 19–21, 23–26, 28–34, 36–41]; de-
tection bias was high in eight (29.6%) studies [15, 19, 21,
23, 26, 31, 33, 35], and allocation concealment was
found in four (14.8%) studies [15, 26, 27, 35]. In most of
the studies, blinding of participants and staff was not
possible due to the nature of the intervention.
Effectiveness of the interventions
Medication appropriateness
Meta-analysis of medication appropriateness (Fig. 4) in-
cluding 6754 residents [15, 17, 23–27, 30, 31, 37–39]
showed a significant improvement on medication appro-
priateness (RR 0.71; 95% confidence interval (CI): 0.60,
0.84, despite high heterogeneity (P < 0.00001; I2 = 91%).
This outcome was assessed for the intervention subtypes
of staff education (RR 0.66, 95% CI:0.43, 1.01), imple-
mentation of multi-disciplinary case conferencing (RR
0.97,95% CI:0.92, 1.03) computerised clinical decision
support systems (RR 0.78, 95% CI:0.64, 0.95) and medi-
cation review (RR 0.62 95% CI:0.41, 0.93) (See Fig. 5).
The standardised mean difference of medication ap-
propriateness scales for the remaining two Crotty et al.
studies [24, 25] was calculated separately (standardised
mean difference = − 0.67; 95% CI: − 0.97, − 0.36) with a
heterogeneity of I2 = 3%.
Other outcomes
Hospital admission
Meta-analysis of hospital admission (Fig. 6) as an out-
come measure investigated in 11,272 residents resulted
in the analysis of eight studies [25, 28, 33, 34, 37, 38, 40,
41] (10,610 residents), which showed that interventions
have no effect on hospital admission RR = 1.00, 95% CI:
0.93,1.06) with a heterogeneity of I2 = 0%.
Fig. 3 Risk of bias summary
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Mortality
Meta-analysis of mortality (Fig. 7) as an outcome meas-
ure investigated in 13,675 residents [21–23, 28, 33, 34,
37, 39, 40] showed no significant difference between the
intervention group and control group (RR 0.98, 95% CI:
0.86,1.11, P = 0.07) with a heterogeneity of I2 = 43%.
Falls
Meta-analysis of falls (Fig. 8) as an outcome measure in-
vestigated in 9382 residents [26–28, 31, 33, 38, 41]
showed that interventions had no effect on falls (RR =
1.06; 95%CI: 0.89,1.26) with a heterogeneity of I2 = 87%.
Medication- related problems
Claesson and Schmidt et al. [18, 20] found 819 medica-
tion -related problems in 395 participants resulting in an
action taken in 90% (737) with withdrawal of a drug in
368 (45%) and change of medications in 162 (20%). Fur-
niss et al. [21] reported that 239 (92%) of 261 recom-
mendations were accepted by the GP resulting in change
in therapy in 144 patients. The most common reasons
for recommendations (33%) were the medication indica-
tion was no longer present. Roberts et al. [23] found that
medication reviews resulted in changes to medications
in 54 (39%) of residents. Crotty et al. [25] reported that
the most common medication-related problem identified
in control and intervention groups was that the residents
were allocated to a new family physician when transfer
to long-term care facility (n = 35, 62.5% intervention;
n = 41, 75.9% control). Zermansky et al. [28] found a sig-
nificant difference in the mean number of drug changes
per resident (mean 3.1, SD = 2.7 for intervention and
mean 2.4, SD = 2.6 for control) (P < 0.0001). Milos et al.
[36] found similar number of drug-related problems be-
tween community-dwelling patients (mean 2.55, SD =
1.29) and nursing home residents (mean 2.53, SD = 1.33)
(p = 0.767). 56% of drug-related problems resulted in an
action taken and change of medications (mean 1.44,
SD = 1.33) with no difference between the community
dwelling and the nursing home patients (p = 0.946).
Frankenthal et al. [37] made 327 recommendations - 245
in 129 residents based on STOPP and 82 in 65 residents
based on START. The physician accepted 82.4% of
STOPP recommendations and 92.6% of START
recommendations.
Quality of Life (QoL)
Meta-analysis of quality of life (Fig. 9) outcomes in 570
residents, of a total of 1141 residents that included QoL
as an outcome measure, found that the interventions
had no effect on residents’ QoL (standardised mean dif-
ference = 0.16 95% CI:-0.13, 0.45) with a heterogeneity of
I2 = 57% between trials [37, 39, 41]. Pitkala et al. [39] re-
ported that health-related QoL in the intervention group
(− 0.038, 95% CI: − 0.054, − 0.022) declined more slowly
than in control group during 12-month follow-up (−
0.072, 95% CI: − 0.089, − 0.055). Frankenthal et al. [37]
found no significant difference between groups in the
a
b
Fig. 4 a: A meta-analysis of the effect of interventions on medication appropriateness. b: Standardised mean difference in the change of MAI
score comparing experimental (intervention) group and control group
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physical average score (intervention mean 33.1 ± 8.1,
control mean 33 ± 8.3, p = 0.09) and mental components
(intervention mean 37.7 ± 1.7, control mean 39.6 ± 11.3
p = 0.70) of the SF-12 questionnaire.
BPSD
Of 1941 residents examined, pooled analysis of BPSD of
two studies [15, 27] comprising 419 residents showed no
Fig. 5 Subgroup analysis of the effect of interventions medication review, multi-disciplinary team meetings, staff education and computerised
clinical decision
Fig. 6 A meta-analysis of the effect of interventions on hospital admission
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significant change after the intervention (RR 0.68, 95%
CI: 0.44,1.06; I2 =0%) (Fig. 10).
ADEs
Of the 1206 residents [25, 29] examined for ADEs after
the intervention. Neither of the two RCTs reported any
statistically significant differences in ADEs between the
intervention and control groups. The RR for all ADEs
was 1.04 (95% CI: 0.96,1.13; I2 =0%) (Fig. 11).
Cognitive function
Meta-analysis of 145 residents [15, 35] indicated that the
interventions had no effect on cognitive function
(weighted mean difference = 0.69, 95%CI: − 1.25, 2.64)
(Fig. 12). No heterogeneity was detected between trials
(I2 =0).
Discussion
This systematic review examined how a wide variety of
interventions optimise medications prescribed in nursing
homes, when applied either individually or through
multi-faceted approaches. Our meta-analysis of available
data showed that the interventions implemented in the
included studies can improve medication appropriate-
ness in older residents, although heterogeneity was high
among included studies. Whilst these results were prom-
ising, the impact on the residents’ clinical outcomes was
undetectable. There was limited evidence for effective-
ness of interventions in reducing hospitalisation, all-
cause mortality, falls, ADEs, cognitive function or BPSD.
There are several published systematic reviews on clin-
ical outcomes of different interventions conducted in aged
care homes. In a review by Forsetlund and colleagues [11],
the authors found that both educational outreach/educa-
tional interventions and medication review by pharmacists
under certain situations could reduce inappropriate drug
use in nursing homes. However, they reported that the
evidence was of poor quality and too low to assess the ef-
fect of the interventions on health outcomes. A review by
Loganathan et al. [12] grouped the interventions into four
Fig. 7 A meta-analysis of the effect of interventions on mortality
Fig. 8 A meta-analysis of the effect of interventions on falls
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groups (staff education including academic detailing,
multi-disciplinary team meetings, medication review, and
computerised clinical decision support system). No one
interventional strategy was found to be effective. However,
the most promising intervention seems to be education
including academic detailing. That review reported that
multifaceted interventions are likely to be required to im-
prove prescribing in care homes [12]. A narrative review
by Shafiee et al. [10], which included 18 studies, seven of
them RCTs, found that the interventions may improve
medication appropriateness in people with dementia in
any settings, but the evidence for the effect of the inter-
ventions on health outcomes remained uncertain.
Our findings on clinical outcomes are in line with that
of previous reviews [43, 44], which found no evidence
for the interventions impacting resident’s clinical out-
comes such as ADEs, mortality, QoL and hospital admis-
sion. Since the elderly often exhibit non-specific clinical
symptoms such as depression, constipation, falls and
confusion, it is difficult to detect ADEs as opposed to
the general condition of the residents. Another possible
reason for the lack of significant effect of interventions
on falls and ADEs may be the potential for underreport-
ing of incidents that were obtained from nursing re-
cords. The lack of effect of interventions on QoL in the
treatment group compared to the control may be attrib-
uted to the wide variation in the length of the follow up
period (3–12months) [43].
Interventions that focus on individual team members
may had limited effectiveness in busy clinical environ-
ment. For example, the educational intervention deliv-
ered by a pharmacist [26] failed to have any significant
effect on major outcomes. The investigators
demonstrated that the lack of effect was attributed to
staff attrition, short study duration, and not all the phy-
sicians in the recruited homes participated in the study.
Very few of the interventions were based on strong
theoretical foundations. An exception was the educa-
tional study by Pitkälä et al. [39], who suggested that the
use of constructive learning theory to recognise poten-
tially harmful medications was more likely to change
practice in healthcare than using lectures alone. Deficits
in the education of health careworkers were thought to
be important. Forsetlund et al. [11] suggested that health
care providers receive inadequate training in geriatric
medications in their education. Therefore, any interven-
tion for minimising medications usually requires some
form of education.
Although our primary focus was on clinical outcomes,
some interventions demonstrated a decrease in
medication-related costs. Frunsis et al. [21] reported a
reduction in the cost of medicine per resident over 4
months period by 27.47 GB Pounds in the intervention
group. Roberts et al. [23] reported savings in drug cost
(64 AUD/ resident/year in intervention group) in the
clinical pharmacy program. Frankenthal et al. [37] found
a significant reduction in the average monthly costs of
medications in the intervention group ILS 279 ± 171.9
compared to baseline ILS 382.7 ± 279 (P < 0.001) at 12
months follow-up period. Pope et al. [34] reported a net
reduction in medication cost in intervention group over
a 6-month period. While, Crotty et al. [24] reported
similar Pharmaceutical Benefit Scheme (PBS) monthly
drug costs of regular medications between groups (mean
AUD 359 in intervention versus AUD 303 in control
(P = 0.837). These interventions require resources and
Fig. 9 A meta-analysis of the effect of interventions on quality of life (QoL)
Fig. 10 A meta-analysis of the effect of interventions on Behavioural and Psychological Symptoms of Dementia (BPSD)
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therefore, evaluating these interventions economically
and their cost-effectiveness should be considered in fu-
ture research.
Strengths and limitations
This systematic review was based on a comprehensive
search of the literature that was limited to 25 studies
with robust design (RCT, cRCT) and compared to previ-
ous reviews on related topics [12, 44], our sample size
may be regarded as sufficiently powered.
Another strength of this review was a focus only on
residents in care homes. The nursing home population
is at heightened risk of receiving multiple drugs because
of their comorbidities. Therefore, evaluating specific
available interventions optimising medications in this
setting is required. We were able to complete meta-
analyses to pooled the overall effects.
This study is not without limitations. We included
only English language publications, which may lead to
potential omission of other interventions. Although
MEDLINE, PubMed, Google scholar, and PsycINFO da-
tabases were searched for relevant articles, some studies
indexed in other databases may have been missed. We
identified several additional articles manually which may
indicate poor indexing of older studies and a lack of
consistent terminology.
Due to the nature of the interventions, performance
and detection biases may have resulted from the diffi-
culty in maintaining blinding. Meta-analysis of some
studies was difficult due to the variations in the
measurement of specific outcomes. Certain outcomes,
such as cognitive function, were examined in a lim-
ited number of articles, reducing the power of the
analysis. Further, certain studies were small or had
short study periods, which may potentially limit the
effect of an intervention on the outcomes. We
attempted to evaluate medication-related problems
such as drug interactions, number of pharmacist rec-
ommendations etc. but these outcomes were not con-
sistently reported in the studies and this our ability to
draw any robust conclusions was limited.
Heterogeneity was notable among some studies in-
cluded in the meta-analysis. The factors that caused this
heterogeneity were difficult to discern. Due to differ-
ences in training, the characteristics of the nursing home
residents, healthcare culture, the number of physicians’
visits and their usual practices the ability to generalise
findings from one country to another is difficult.
Implications for research and practice
In view of the considerable investment in strategies
aimed at improving medication appropriateness in
RACFs worldwide, our findings question the value of
such interventions based on the apparent lack of out-
comes that may be meaningful to RACF residents.
Large, high quality RCT studies are required to
identify effective interventions to optimise medications
used in RACFs. Regarding physicians or staff accept-
ance of the intervention, only limited information was
provided in the studies. Further qualitative study
Fig. 12 A meta-analysis of the effect of interventions on cognitive function
Fig. 11 A meta-analysis of the effect of interventions on adverse drug events (ADEs)
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utilising semi-structured interviews may provide use-
ful information to obtain the opinion of healthcare
professionals with regard to process outcomes, such
as whether the intervention was perceived to be suc-
cessful or not, and to identify the potential means to
overcome the barriers to changing professional behav-
iour by this method. More intensive interventions on
medical and care staff with more stringent monitoring
may be required.
Conclusion
This systematic review found that multifaceted interven-
tions including medication review, staff education/train-
ing, multi-disciplinary case-conferencing and clinical
decision support technology could improve the appro-
priateness of medications at RACFs. However, evidence
for the effect of these interventions on residents’ clinical
outcomes was scarce and no conclusion could be drawn.
More robust clinical studies are required to ascertain the
health outcomes benefits.
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